Adrenal cortical carcinoma.
Adrenal cortical carcinoma is a rare endocrine tumor, and complete surgical resection is the only potentially curative treatment. Accurate preoperative biochemical and radiographic evaluation of the patient who presents with an adrenal mass optimizes patient management and facilitates a complete margin-negative resection of the primary tumor--the most important prognostic variable for long-term survival. Response to mitotane or chemotherapy is modest in patients with advanced disease. It is hoped that an improved understanding of the molecular pathogenesis of this challenging tumor will lead to the development of novel treatment strategies.
Boushey
R P
RP
Department of Surgical Oncology, Section of Endocrine Surgery, Princess Margaret Hospital, University of Toronto, 610 University Avenue, Suite 3-130, Toronto, Ontario, Canada M5G 2M9.
Dackiw
A P
AP
D000306:Adrenal Cortex Neoplasms / Q000150:complications / Q000453:epidemiology / Q000378:metabolism / Q000601:surgery; D000315:Adrenalectomy / Q000379:methods; D000328:Adult; D000465:Algorithms; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002277:Carcinoma / Q000150:complications / Q000453:epidemiology / Q000378:metabolism / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D002675:Child, Preschool; D003131:Combined Modality Therapy; D003480:Cushing Syndrome / Q000188:drug therapy / Q000209:etiology; D004812:Epidemiologic Methods; D005260:Female; D006801:Humans; D006929:Hyperaldosteronism / Q000188:drug therapy / Q000209:etiology; D015994:Incidence; D008297:Male; D008875:Middle Aged; D008901:Mineralocorticoids / Q000008:administration & dosage; D008939:Mitotane / Q000627:therapeutic use; D013148:Spironolactone / Q000627:therapeutic use; D013256:Steroids / Q000378:metabolism; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D008901:Mineralocorticoids; D013256:Steroids; D013148:Spironolactone; D008939:Mitotane